% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • the007doc the007doc Sep 29, 2012 8:20 AM Flag


    but the ignorant will say the p values are not less than 0.05 as they cannot understand the trial or the interim look.

    Glad I am long.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hopefully we see $10 soon!

      Sentiment: Strong Buy

    • efficient_frontier2002 efficient_frontier2002 Sep 29, 2012 11:48 AM Flag

      These p-values ARE getting close to significance ("Progression free survival in the full data set was 2.8 months vs. 4.2 months (p=0.076) and overall response rate was 8% vs. 16% (p=0.078) for D vs. G+D, respectively."), and with a tripling of N in Phase 3 (from 172 to 500) have an excellent chance of reaching significance.

      Plus, take a look at these ALREADY significant p's (0.01 and 0.02) ...

      Survival outcomes for the remaining populations defined by the specified stratification factors (D vs. G+D):

      Time since diagnosis
      advanced disease 6 mo 50%) subsets of the all-adeno population. It sounds like Synta will soon be discussing with regulatory agencies how it can best use this data in the Phase 3.

      Finally, it doesn't hurt that the poster's Kaplan-Meier overall survival chart looks like median-OS will probably hit 13-16 months after factoring in the flattening of the curve in the day 240-340 part of the graph. In ohter words, about a double vs. the control arm median-OS of 7.4 months.!!

0.3430.000(0.00%)Jul 22 4:00 PMEDT